Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Is UVC the Future of Infection Prevention Technology?

The risk of cross-contamination and mass infections in healthcare settings has always been an issue, but in the midst of a raging pandemic, that problem has been exacerbated even further. However, with many hospitals, nursing homes and other healthcare facilities already stretched thin, an affordable solution that requires minimal time and effort to use is…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Is UVC the Future of Infection Prevention Technology?

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The risk of cross-contamination and mass infections in healthcare settings has always been an issue, but in the midst of a raging pandemic, that problem has been exacerbated even further.

However, with many hospitals, nursing homes and other healthcare facilities already stretched thin, an affordable solution that requires minimal time and effort to use is needed. Can UVC technology fill this gap?

Daniel Litwin met with Christopher Allen, CEO of iCleanse, to get his thoughts on the matter. iCleanse is a chemical-free disinfection company that uses UVC light to disinfect surfaces and spaces in 60 seconds or less, with Allen bringing over a decade of experience in IoT technology to the organization.

The COVID-19 pandemic has quickly brought UVC technology to the forefront of infection prevention strategies in the healthcare setting, establishing it as the standard that all other technologies must follow.

One additional, unexpected benefit that UVC products offer healthcare companies is increased employee satisfaction.

“It’s so hard to find new folks to come on board, and there’s a shortage in general,” Allen said. “So, giving them the opportunity to disinfect their phone and tablet, whatever’s in their pocket, before they come to the facility, but also when they go home to their families – that gives them a lot of peace of mind that they are not bringing COVID home with them and not exposing their children or their loved ones to this pandemic.”

Visit surfacide.com for more information on the services and solutions we offer. Make sure to subscribe to A Move in the Light Direction, for the latest insights on how to create a safer environment wherever you go.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512